Newamsterdam Pharma Company N.V. (NAMS)

$18.53 +0.42 (2.32%)
Market Cap 2.08B
Revenue (ttm) 45.56M
Net Income (ttm) -241.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -530.29%
Debt to Equity Ratio 0.00
Volume 257,794
Avg Vol 793,190
Day's Range N/A - N/A
Shares Out 112.27M
Stochastic %K 19%
Beta -0.03
Analysts Strong Sell
Price Target $42.60

Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewA...

Industry: Biotechnology
Sector: Healthcare
Phone: 31 35 206 2971
Address:
Gooimeer 2-35, Naarden, Netherlands
TrendEdgeLogan
TrendEdgeLogan Jun. 28 at 5:27 PM
$NAMS $2.44B mc, founder-led. $XBI stock to watch due to ongoing unplanned open market share purchases, including last week. Director bought $69K in shares, adding to his $167K bullish bet from the prior week. - Pct of funds long is increasing long-term but fell last quarter - Short float pct is rising long-term, a conflicting signal to monitor ⚠️ TrendEdge.app/asset/NAMS
0 · Reply
vinkush1
vinkush1 Jun. 27 at 4:13 AM
$NAMS insider bought should I start a position?
1 · Reply
djohnson591
djohnson591 Jun. 26 at 1:24 PM
$ESPR $NAMS It's coming along nicely 😂😂😂. Here's my prediction: - Dec24 - run NAMS up and do an offering (start to secure massive short) - Dec24 - use NAMS news to start the knockdown of ESPR heading into Q1 - Dec24 - Secure ESPR debt refi - 1stH-25 - Tank ESPR, shift shares around, cover shorts - 1stH-25 - Secure massive short position in NAMS - 2ndH-25 - Announce something that rockets ESPR stock and puts pressure on competitors - 2ndH-25 - Tank NAMS stock and profit on newly secured short position Sound about right? - 😂😂😂 Buying as much ESPR as I can get my hands on bitches!!!
2 · Reply
hschlauch
hschlauch Jun. 22 at 4:19 PM
$ESPR $NAMS $AMGN This referenced study contains major issues. I’ve gone through the actual data and here’s what I found: 1. The separation between “high” and “low” hsCRP groups was split at a median of 1.90 mg/l (50% above and 50% below that point)! Long term HRs for first MACE are typically not significant until well-beyond that point. In fact, the entire study population’s upper quartile begins at an hsCRP of only 3.42 mg/l. That’s like extrapolating data on a group of people smoking a few cigarettes every month and claiming there is sparse evidence for increased cancer risk among ALL cigarette smokers. Increased long term risk of first MACE is barely getting started for hsCRP at 2-3 mg/l.
6 · Reply
BRLondon
BRLondon Jun. 21 at 2:59 PM
$ESPR $NAMS From your own source @masonat BA = statins... But without the main statins side effects...
1 · Reply
Canyonfundstrader2007
Canyonfundstrader2007 Jun. 18 at 10:21 PM
$ESPR $NAMS NEXLIZET #1 Statin Alternative
0 · Reply
Canyonfundstrader2007
Canyonfundstrader2007 Jun. 18 at 10:12 PM
$NAMS $ESPR Studies >
0 · Reply
Canyonfundstrader2007
Canyonfundstrader2007 Jun. 18 at 10:11 PM
$ESPR $NAMS Esperion drug NEXLIZET years ahead & NO side-effects with excellent results 38% to 50% reduction OF LDL & 35% reduced hsCRP levels. Has the only FDA primary prevention label as a statin alternative.
0 · Reply
masonat
masonat Jun. 18 at 6:32 PM
$NAMS IL-6 is a far more relevant marker for inflammation in ASCVD than hs-CRP. hs-CRP has no significant predictive value for MACE after adjusting for elevated IL-6. Some drugs that reduce CRP also reduce IL-6 (ie statins, ziltivekimab), but bempedoic acid has no impact on IL-6. Thus, its hs-CRP reduction likely has little to no effect on MACE. One day the ESPR bulls may stop spamming this board with "primary prevention!" and "hs-CRP!" but today is not that day. https://www.atherosclerosis-journal.com/article/S0021-9150(24)00021-2/abstract
1 · Reply
Canyonfundstrader2007
Canyonfundstrader2007 Jun. 18 at 5:33 PM
$ESPR $NAMS $AMGN HUge value
0 · Reply
Latest News on NAMS
NewAmsterdam Pharma Announces Positive Topline Alzheimer's Disease Data from BROADWAY Clinical Trial

Jun 9, 2025, 7:00 AM EDT - 22 days ago

NewAmsterdam Pharma Announces Positive Topline Alzheimer's Disease Data from BROADWAY Clinical Trial

NewAmsterdam Pharma to Host R&D Day on June 11, 2025

Jun 5, 2025, 8:00 AM EDT - 26 days ago

NewAmsterdam Pharma to Host R&D Day on June 11, 2025

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June

May 27, 2025, 8:00 AM EDT - 5 weeks ago

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June

NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference

May 14, 2025, 8:00 AM EDT - 6 weeks ago

NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

May 8, 2025, 8:00 AM EDT - 7 weeks ago

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025

May 7, 2025, 7:15 AM EDT - 7 weeks ago

NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 2, 2025, 4:01 PM EDT - 2 months ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress

Apr 30, 2025, 8:00 AM EDT - 2 months ago

NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress

NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 31, 2025, 8:00 AM EDT - 3 months ago

NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference

NewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of Obicetrapib

Feb 28, 2025, 11:26 PM EST - 4 months ago

NewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of Obicetrapib

NewAmsterdam Pharma: A Mispriced Bet On A Cholesterol Revolution

Feb 28, 2025, 10:48 AM EST - 4 months ago

NewAmsterdam Pharma: A Mispriced Bet On A Cholesterol Revolution

NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update

Feb 26, 2025, 8:00 AM EST - 4 months ago

NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March

Feb 25, 2025, 8:00 AM EST - 4 months ago

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March

NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Dec 13, 2024, 5:16 PM EST - 7 months ago

NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Dec 11, 2024, 9:37 PM EST - 7 months ago

NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

NewAmsterdam Pharma: Positive Obicetrapib Data Leads To New Catalysts

Dec 11, 2024, 1:33 PM EST - 7 months ago

NewAmsterdam Pharma: Positive Obicetrapib Data Leads To New Catalysts

Top 3 Health Care Stocks That May Collapse This Quarter

Dec 11, 2024, 6:55 AM EST - 7 months ago

Top 3 Health Care Stocks That May Collapse This Quarter

ADPT FNA

NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Dec 10, 2024, 4:34 PM EST - 7 months ago

NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday?

Dec 10, 2024, 11:14 AM EST - 7 months ago

Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday?

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia

Dec 10, 2024, 7:00 AM EST - 7 months ago

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia

NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024

Nov 18, 2024, 3:20 PM EST - 8 months ago

NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024

NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November

Oct 28, 2024, 4:30 PM EDT - 8 months ago

NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November

Obicetrapib Positions NewAmsterdam Pharma For Significant Market Growth In Cardiovascular Therapies

Oct 4, 2024, 12:09 PM EDT - 9 months ago

Obicetrapib Positions NewAmsterdam Pharma For Significant Market Growth In Cardiovascular Therapies

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September

Aug 30, 2024, 8:00 AM EDT - 10 months ago

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September

NewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside

Aug 28, 2024, 1:33 PM EDT - 10 months ago

NewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside

NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024

Jul 26, 2024, 4:01 PM EDT - 1 year ago

NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024

NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors

Jul 8, 2024, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors

NewAmsterdam Pharma: Cholesterol Drug Treatment With Catalysts In 1-Year Period

Jul 5, 2024, 1:40 PM EDT - 1 year ago

NewAmsterdam Pharma: Cholesterol Drug Treatment With Catalysts In 1-Year Period

NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease

Apr 9, 2024, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease

BioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of Directors

Apr 9, 2024, 8:00 AM EDT - 1 year ago

BioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of Directors

NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer

Apr 1, 2024, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer

NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress

Mar 25, 2024, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress

NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD

Mar 12, 2024, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD

NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update

Feb 28, 2024, 8:00 AM EST - 1 year ago

NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update

NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Feb 13, 2024, 10:40 PM EST - 1 year ago

NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants

Feb 13, 2024, 4:01 PM EST - 1 year ago

NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants

NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Feb 1, 2024, 4:01 PM EST - 1 year ago

NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

NewAmsterdam Pharma Announces 2024 Strategic Priorities

Jan 4, 2024, 8:00 AM EST - 1 year ago

NewAmsterdam Pharma Announces 2024 Strategic Priorities

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights

Nov 13, 2023, 8:00 AM EST - 1 year ago

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights

NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer

Oct 23, 2023, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer

Tessellate BIO Emerges from Stealth

Oct 17, 2023, 3:00 AM EDT - 1 year ago

Tessellate BIO Emerges from Stealth

REPL

NewAmsterdam Pharma's Pioneering Pulse On Alzheimer's Breakthroughs

Oct 2, 2023, 9:26 PM EDT - 1 year ago

NewAmsterdam Pharma's Pioneering Pulse On Alzheimer's Breakthroughs

NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer's Disease Who Carry an ApoE4 Mutation

Sep 21, 2023, 7:00 AM EDT - 1 year ago

NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer's Disease Who Carry an ApoE4 Mutation

NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference

Sep 20, 2023, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference

NewAmsterdam Pharma: Best Cardiovascular Biotech In 2023

Aug 19, 2023, 1:10 PM EDT - 2 years ago

NewAmsterdam Pharma: Best Cardiovascular Biotech In 2023

NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer

Aug 14, 2023, 4:01 PM EDT - 2 years ago

NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights

Aug 7, 2023, 7:15 AM EDT - 2 years ago

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights

NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular Disease

Jul 25, 2023, 4:01 PM EDT - 2 years ago

NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular Disease

NewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary Shares

Jun 9, 2023, 4:01 PM EDT - 2 years ago

NewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary Shares

NewAmsterdam Pharma Announces Pricing of Upsized Secondary Offering of Ordinary Shares

Jun 6, 2023, 11:25 PM EDT - 2 years ago

NewAmsterdam Pharma Announces Pricing of Upsized Secondary Offering of Ordinary Shares

TrendEdgeLogan
TrendEdgeLogan Jun. 28 at 5:27 PM
$NAMS $2.44B mc, founder-led. $XBI stock to watch due to ongoing unplanned open market share purchases, including last week. Director bought $69K in shares, adding to his $167K bullish bet from the prior week. - Pct of funds long is increasing long-term but fell last quarter - Short float pct is rising long-term, a conflicting signal to monitor ⚠️ TrendEdge.app/asset/NAMS
0 · Reply
vinkush1
vinkush1 Jun. 27 at 4:13 AM
$NAMS insider bought should I start a position?
1 · Reply
djohnson591
djohnson591 Jun. 26 at 1:24 PM
$ESPR $NAMS It's coming along nicely 😂😂😂. Here's my prediction: - Dec24 - run NAMS up and do an offering (start to secure massive short) - Dec24 - use NAMS news to start the knockdown of ESPR heading into Q1 - Dec24 - Secure ESPR debt refi - 1stH-25 - Tank ESPR, shift shares around, cover shorts - 1stH-25 - Secure massive short position in NAMS - 2ndH-25 - Announce something that rockets ESPR stock and puts pressure on competitors - 2ndH-25 - Tank NAMS stock and profit on newly secured short position Sound about right? - 😂😂😂 Buying as much ESPR as I can get my hands on bitches!!!
2 · Reply
hschlauch
hschlauch Jun. 22 at 4:19 PM
$ESPR $NAMS $AMGN This referenced study contains major issues. I’ve gone through the actual data and here’s what I found: 1. The separation between “high” and “low” hsCRP groups was split at a median of 1.90 mg/l (50% above and 50% below that point)! Long term HRs for first MACE are typically not significant until well-beyond that point. In fact, the entire study population’s upper quartile begins at an hsCRP of only 3.42 mg/l. That’s like extrapolating data on a group of people smoking a few cigarettes every month and claiming there is sparse evidence for increased cancer risk among ALL cigarette smokers. Increased long term risk of first MACE is barely getting started for hsCRP at 2-3 mg/l.
6 · Reply
BRLondon
BRLondon Jun. 21 at 2:59 PM
$ESPR $NAMS From your own source @masonat BA = statins... But without the main statins side effects...
1 · Reply
Canyonfundstrader2007
Canyonfundstrader2007 Jun. 18 at 10:21 PM
$ESPR $NAMS NEXLIZET #1 Statin Alternative
0 · Reply
Canyonfundstrader2007
Canyonfundstrader2007 Jun. 18 at 10:12 PM
$NAMS $ESPR Studies >
0 · Reply
Canyonfundstrader2007
Canyonfundstrader2007 Jun. 18 at 10:11 PM
$ESPR $NAMS Esperion drug NEXLIZET years ahead & NO side-effects with excellent results 38% to 50% reduction OF LDL & 35% reduced hsCRP levels. Has the only FDA primary prevention label as a statin alternative.
0 · Reply
masonat
masonat Jun. 18 at 6:32 PM
$NAMS IL-6 is a far more relevant marker for inflammation in ASCVD than hs-CRP. hs-CRP has no significant predictive value for MACE after adjusting for elevated IL-6. Some drugs that reduce CRP also reduce IL-6 (ie statins, ziltivekimab), but bempedoic acid has no impact on IL-6. Thus, its hs-CRP reduction likely has little to no effect on MACE. One day the ESPR bulls may stop spamming this board with "primary prevention!" and "hs-CRP!" but today is not that day. https://www.atherosclerosis-journal.com/article/S0021-9150(24)00021-2/abstract
1 · Reply
Canyonfundstrader2007
Canyonfundstrader2007 Jun. 18 at 5:33 PM
$ESPR $NAMS $AMGN HUge value
0 · Reply
Canyonfundstrader2007
Canyonfundstrader2007 Jun. 18 at 5:32 PM
$ESPR $NAMS $AMGN extremely valuable
0 · Reply
Canyonfundstrader2007
Canyonfundstrader2007 Jun. 18 at 5:31 PM
$ESPR NEXLIZET & NEXLETOL are the ONLY Statin alternative drugs to lower LDL & HS-CRP levels. They are also the only FDA labeled drugs for primary prevention. $NAMS $AMGN can't compete.
0 · Reply
JarvisFlow
JarvisFlow Jun. 17 at 12:00 PM
Citigroup has updated their rating for NewAmsterdam Pharma Co ( $NAMS ) to Buy with a price target of 42.
0 · Reply
masonat
masonat Jun. 17 at 1:32 AM
$NAMS it's been stated many times by management that "the bar" for non-statins has already been set by the PCSK9s for MACE reduction at 15%. But I totally forgot that inclisiran has a CVOT readout in mid 2026 (it's been *so long* I started to think they weren't even doing one). I expect very good results given median follow-up time will be ~5 years. It should easily surpass 15% and maybe even 25%+, but that's largely dependent on the baseline LDL which I can't seem to find published anywhere. I still believe obi will easily clear evolocumab, alirocumab and bempedoic acid but not sure it will beat inclisiran. We'll see how much extra lifting Lp(a) and small LDL-P reductions do but at the end of the day inclisiran is another PCSK9 inhibitor and will not have the extra non-MACE benefits that obi has.
0 · Reply
masonat
masonat Jun. 14 at 3:27 PM
$NAMS reminder that obicetrapib reduces LDL-P as much as a high dose statin and small LDL-P much more than anything on the market.
0 · Reply
JarvisFlow
JarvisFlow Jun. 12 at 10:30 AM
Needham has adjusted their stance on NewAmsterdam Pharma Co ( $NAMS ), setting the rating to Buy with a target price of 40.
0 · Reply
masonat
masonat Jun. 11 at 8:47 PM
$NAMS solid R&D day. Obicetrapib is more differentiated than any other LLT on the market or in development. If obicetrapib simply maintains the results from Broadway into Prevail then it will be the safest *and* most effective non statin LLT available. Company sounds surprisingly bullish on alzheimer's. I'll wait to see the data before I get my hopes up.
1 · Reply
newfguy
newfguy Jun. 11 at 8:33 PM
$NAMS BTFD
0 · Reply
StockAnalyticsAI
StockAnalyticsAI Jun. 11 at 5:59 PM
$NAMS Deep Dive https://youtu.be/ri2zK3ve08o?si=JDpR1tZC5YnKFx3Y
0 · Reply
newfguy
newfguy Jun. 11 at 2:26 PM
$NAMS this company is below the market's radar. Massive opportunity ahead
0 · Reply
newfguy
newfguy Jun. 11 at 2:06 PM
$NAMS https://www.sec.gov/Archives/edgar/data/1936258/000095017025084663/nams-ex99_1.htm
0 · Reply
EPSMomentumStocks
EPSMomentumStocks Jun. 11 at 12:07 PM
These stocks are experiencing exceptionally elevated levels of dollar inflow, indicating strong institutional interest and significant capital allocation activity $MANU $NAMS $MU $SOFI $LEGN #stocks #trading #investing
0 · Reply